Have a feature idea you'd love to see implemented?
Let us know!
VNRX Volitionrx Ltd
Price (delayed)
$0.811
Market cap
$75.15M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.36
Enterprise value
$75.62M
Volition is a multi-national epigenetics company developing simple, easy to use, costeffective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to
Highlights
The revenue has surged by 98% year-on-year and by 32% since the previous quarter
The gross profit has soared by 98% YoY and by 32% QoQ
The quick ratio has plunged by 69% YoY and by 5% from the previous quarter
VNRX's debt is up by 37% YoY
Key stats
What are the main financial stats of VNRX
Market
Valuations
Earnings
Shares outstanding
92.66M
Market cap
$75.15M
Enterprise value
$75.62M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
55.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
58.81
Revenue
$1.29M
EBIT
-$29.57M
EBITDA
-$28.22M
Free cash flow
-$14.53M
Per share
Balance sheet
Liquidity
EPS
-$0.36
Free cash flow per share
-$0.17
Book value per share
-$0.23
Revenue per share
$0.01
TBVPS
$0.14
Total assets
$12.68M
Total liabilities
$35.32M
Debt
$5.89M
Equity
-$21.5M
Working capital
-$23.48M
Debt to equity
-0.27
Current ratio
0.22
Quick ratio
0.19
Net debt/EBITDA
-0.02
Margins
Efficiency
Dividend
EBITDA margin
-2,194.4%
Gross margin
100%
Net margin
-2,323.2%
Operating margin
-2,331.9%
Return on assets
-163.4%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-2,299.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VNRX stock price
How has the Volitionrx stock price performed over time
Intraday
0.12%
1 week
12.64%
1 month
10.94%
1 year
20.15%
YTD
13.11%
QTD
34.94%
Financial performance
How have Volitionrx's revenue and profit performed over time
Revenue
$1.29M
Gross profit
$1.29M
Operating income
-$29.98M
Net income
-$29.87M
Gross margin
100%
Net margin
-2,323.2%
The revenue has surged by 98% year-on-year and by 32% since the previous quarter
The gross profit has soared by 98% YoY and by 32% QoQ
The company's operating margin has surged by 57% YoY and by 31% QoQ
VNRX's net margin has soared by 55% YoY and by 30% QoQ
Growth
What is Volitionrx's growth rate over time
Valuation
What is Volitionrx stock price valuation
P/E
N/A
P/B
N/A
P/S
55.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
58.81
The company's EPS rose by 32% YoY and by 10% QoQ
The stock's P/S is 99% below its 5-year quarterly average of 3875.6 and 6% below its last 4 quarters average of 59.0
The revenue has surged by 98% year-on-year and by 32% since the previous quarter
Efficiency
How efficient is Volitionrx business performance
The company's return on sales has surged by 56% YoY and by 30% QoQ
Dividends
What is VNRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VNRX.
Financial health
How did Volitionrx financials performed over time
The company's total assets is 64% lower than its total liabilities
The company's total liabilities has surged by 69% YoY
The quick ratio has plunged by 69% YoY and by 5% from the previous quarter
VNRX's debt is 127% higher than its equity
The company's debt to equity has surged by 87% YoY
VNRX's debt is up by 37% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.